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ABSTRACT
Minor ischemic strokes and transient ischemic attacks involve impaired perfusion
to corresponding brain regions leading to neurological deficits that may or may not resolve
after the event. Adults suffering one of these minor neurovascular events have high odds
of a recurrent stroke within the first 90 days, mitigated but not prevented by standard
treatment of clopidogrel and aspirin. Vitamin E alpha-tocopherols have been shown to
reduce platelet aggregation, potentiate aspirin, and reduce ischemic damage. This study
will assess the efficacy of vitamin E alpha-tocopherol, in addition to the standard treatment,
on stroke recurrence in adults with a minor neurovascular event compared to the standard
treatment alone. In this randomized, double-blinded, placebo-controlled trial, participants
will receive the standard treatment of clopidogrel and aspirin with either vitamin E alphatocopherol or placebo supplements. This study may help decrease the proportion of stroke
recurrence and may ultimately reduce morbidity and mortality.

v

CHAPTER 1: INTRODUCTION
1.1 Background
Cerebrovascular accidents, or strokes, are a leading cause of disability in the United
States with 800,000 people suffering from a new or recurrent stroke a year. Strokes may
be due to ischemia, a subarachnoid hemorrhage, or an intracerebral hemorrhage with 87%
of all strokes having an ischemic etiology.1 An ischemic stroke involves arterial occlusion
or blockage resulting in reduced blood perfusion to corresponding brain regions leading to
neurological deficits. Ischemic strokes are subcategorized into mild, moderate, and severe
by the National Institute of Health Stroke Scale (NIHSS), a 42-scale scoring system that is
utilized to quantify stroke severity in patients. A minor ischemic stroke is classified by a
NIHSS score ≤ 3.2-4A transient ischemic attack (TIA) occurs when there is temporary
occlusion of a blood vessel causing brief neurological symptoms that resolve within 24
hours before an ischemic injury occurs. TIA’s precede approximately 15% of all
cerebrovascular accidents and 33% of all ischemic strokes.5,6 The ABCD2 7-scale score
predicts the stroke recurrence risk at 2-days, 7-days, and 90-days in patients who have a
TIA. A patient who has a TIA that is at moderate to high-risk of a recurrent stroke is defined
by an ABCD2 score ≥ 4. 7-9
Unfortunately, both minor ischemic strokes and transient ischemic attacks place
patients at a high-risk of a subsequent stroke with sources suggesting a recurrence risk
ranging from 3-17% within the first 90 days of the primary neurovascular event.10-18 We
propose a trial to reduce stroke recurrence in patients with a primary neurovascular event
using vitamin E supplements. Currently, patients with a moderate to high-risk TIA or minor
ischemic stroke with an identified thrombotic etiology are given antiplatelet therapy to
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prevent a recurrent ischemic event. The regimen that is often prescribed is aspirin and
clopidogrel (DAPT) but the regimen has its limitations.12,13
The Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT)
study was an international, multi-center study that determined that DAPT was associated
with a significantly lower risk of stroke recurrence (hemorrhagic and ischemic) compared
to aspirin alone (HR, 0.74; 95% CI, 0.58 to 0.94). Of note, there was a significant increase
in the risk of major hemorrhage in the DAPT group compared to the aspirin alone group
(0.9% vs 0.4%, HR, 2.32, 95% CI, 1.10 to 4.87).12 In a similar China based trial,
clopidogrel and aspirin were administered for 21 days followed by clopidogrel for the
remainder of 90 days had a significant decrease in recurrent strokes (hemorrhagic and
ischemic) compared to aspirin alone (8.2% vs 11.7%; HR, 0.68; 95% CI, 0.57 to 0.81). 13
DAPT has been shown to decrease stroke recurrence in TIA and minor ischemic stroke
patients when used for less than a month. However, treatment surpasses 1 month, there is
a significant increase in major bleeding events.19 This study aims to determine if there is a
difference in the proportion of patients experiencing recurrent strokes (hemorrhagic or
ischemic) in patients who receive vitamin E alpha-tocopherol supplements in addition to
the standard treatment compared to patients who receive the standard treatment alone after
the initial minor neurovascular event.
There are several mechanisms that vitamin E alpha-tocopherol takes part in that
support its use in this trial. Several studies suggest that alpha-tocopherol inhibits protein
kinase C stimulation (PKC) leading to an increase in nitric oxide (NO) and decrease in free
radicals.20-24 NO then activates cyclic guanosine monophosphate (cGMP) causing
inhibition

of

platelet

aggregation.25,26

In

addition,

alpha-tocopherol

inhibits
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cyclooxygenase (COX) and as a result, when combined with aspirin, antiplatelet effects
are potentiated.22,27,28 If alpha-tocopherol reduces platelet aggregation then it may play a
role in reducing the incidence of secondary ischemic events, including ischemic stroke,
post-minor neurovascular event.
Both animal studies and human studies support the aforementioned mechanism of
vitamin E alpha-tocopherol. Animal studies have shown that both alpha-tocopherol alone
and in combination with aspirin have led to less platelet aggregation and a longer time to
thrombus formation compared to no alpha-tocopherol or aspirin alone, respectively.21,24,29
The studies have also suggested that vitamin E alpha-tocopherol protected cortical neurons
from damage under ischemic conditions.24,28 Human in-vitro studies have further validated
vitamin E alpha-tocopherol’s mechanism through a reduction in platelet aggregation both
alone and in combination with aspirin.22,24,25,30,31 A human in-vivo study showed a
reduction in primary ischemic strokes when used as an oral supplement alone for 6 years
in male smokes compared to male smokers with placebo supplements.32 However, only
one in-vivo study has investigated vitamin E alpha-tocopherol’s effects on stroke
recurrence. A study from 1995 found that 400IU vitamin E alpha-tocopherol plus 325mg
of aspirin for 2 years in patients with a TIA or minor ischemic stroke had a 2% recurrence
risk compared to 12.5% in patient’s taking 325mg aspirin alone (P<0.05). There was a
5.7% recurrence risk of total stroke (hemorrhagic or ischemic) in the vitamin E plus aspirin
group compared to 12.5% in the group that took aspirin alone (P<0.05). Unfortunately, the
study has many limitations and the study has not been reproduced with the current DAPT.33
Despite the preventative treatment for stroke recurrence, there remains to be a high
incidence of disability among patients with a TIA or minor ischemic stroke. New treatment

3

regimens are needed to reduce the burden that this high-risk population faces. Although
vitamin E alpha-tocopherol appears to have a promising mechanism, the literature is
lacking studies that have investigated secondary prevention of stroke recurrence with short
term use of alpha-tocopherol. Given the proposed mechanisms of alpha-tocopherol, this
study aims to determine the association of 200IU vitamin E alpha-tocopherol oral
supplements on stroke recurrence when given for 90 days in addition to the antiplatelet
regimen in patients with a transient ischemic attack or minor ischemic stroke and compare
it to patients taking clopidogrel and aspirin alone. By doing so, it may be possible to reduce
the proportion of stroke recurrence (hemorrhagic or ischemic) in this high-risk population
thus reducing mortality and morbidity.

1.2 Statement of the Problem
Strokes are a leading cause of morbidity and mortality in the United States population.
Although great strides have been made in our understanding of strokes and their
pathophysiologic consequences, they continue to be a daunting experience for physicians
and patients alike. Specifically, there remains to be approximately an 8.2% stroke
(ischemic and hemorrhagic) recurrence risk among patients with a primary transient
ischemic attack or minor ischemic stroke that ultimately leads to disability, death hospital
crowding, and high billing costs.13,34 Approximately one-half of patient’s that experience
a recurrent stroke become disabled.34 By demonstrating the effectiveness of an alternative
treatment regimen, this study may not only reduce the burden among healthcare providers
and the healthcare system, but more importantly the quality of life of people who suffer
from minor neurovascular events.
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Literature suggests vitamin E alpha-tocopherols have antiplatelet, antioxidant, and
aspirin potentiation properties. However, studies lack examining this mechanism with the
current standard treatment in specifically this high-risk population. Therefore, we will
perform a randomized, multi-center, placebo-controlled study to demonstrate the
effectiveness of vitamin E alpha-tocopherol in the prevention of secondary ischemic
strokes and compare it to the currently accepted standard of clopidogrel and aspirin.

1.3 Goals and Objectives
The randomized, multi-center, double-blinded, placebo-controlled trial aims to assess
the efficacy of vitamin E alpha-tocopherol supplements, plus the standard treatment, in
reducing the proportion of stroke recurrence in patients with a primary transient ischemic
attack or minor ischemic stroke compared to the standard treatment alone.

1.4 Hypothesis
Patients with a transient ischemic attack (ABCD2 ≥ 4) or minor ischemic stroke (NIHSS
≤ 3) over the age of 18 years who are treated with 200IU vitamin E alpha-tocopherol in
addition to the standard treatment of aspirin and clopidogrel will have a statistically
significant difference in the proportion of stroke recurrence (hemorrhagic or ischemic)
within 90 days of randomization compared to patients treated with aspirin and clopidogrel
alone.
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1.5 Definitions
ABCD2 Score: A 7-scale score that predicts the risk of stroke recurrence of a person with
a transient ischemic attack. Scoring considers age, blood pressure, clinical features,
duration of symptoms, and diabetes.9 Scoring can be found in Appendix C.
Alpha-Tocopherol: Alpha-tocopherol is one of the eight components of the antioxidant,
vitamin E, and the most predominant form with the chemical formula of C29H50O2.35
Aspirin (Acetylsalicylic Acid/ASA): A synthetic, anti-inflammatory and antiplatelet
agent that non-selectively and irreversibly inhibits COX-1and COX-2 enzymes.
Clopidogrel (Plavix): A synthetic, pharmaceutical, antiplatelet agent that irreversibly
inhibits adenosine phosphate-induced platelet aggregation.
Minor Ischemic Stroke: A minor ischemic stroke is involving occlusion of the brain
vessels resulting in a decrease in blood flow to the corresponding brain structures resulting
in focal deficits. Specifically, a minor ischemic stroke is defined by a NIHSS score ≤ 3.
NIH Stroke Scale (NIHSS): A 42-scale scoring system that is utilized to quantify stroke
severity in patients, taking into consideration the patient’s level of consciousness, gaze
ability, visual ability, facial paralysis, extremity motor drift, lower limb ataxia, sensation,
aphasia, dysarthria, and extinction.4 Full scoring can be found in Appendix E.
Transient Ischemic Attack (TIA): A brief, non-ischemic arterial occlusion in the brain
that causes focal neurological deficits, lasting no longer than 24 hours. A patient with a
TIA with moderate to high risk of stroke recurrence is defined by an ABCD2 score ≥ 4.
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CHAPTER 2: REVIEW OF THE LITERATURE
2.1 Literature Search Strategy
A literature review was conducted between July 2020 and March 2021 using Ovid
(Medline), Scopus, The Cochrane Library, and PubMed with the help of the Yale School
of Medicine librarians. Studies were initially selected based on the title and abstract that
were relevant to our proposed trial. International trials were included into the review based
on the relevance of the study and its contribution to the progression of the literature.
Initially, our research was confined to 2010 but was then extended to 1980 and beyond to
include significant, pertinent trials that contributed to the development of this proposed
trial.
Search strategy utilized the following MeSH headings and terms: TIA, transient
ischemic attack, minor ischemic stroke, ischemic stroke, strokes, vitamin E, vitamin E
alpha-tocopherol, alpha-tocopherol, tocopherols, recurrence, stroke recurrence,
prevention, secondary prevention, treatment, therapy, clopidogrel, aspirin, DAPT, dual
antiplatelet therapy, dual antiplatelet treatment, antiplatelet, platelet aggregation,
thrombosis, antithrombosis, anticoagulation, nitric oxide, NO, vascular, neurovascular,
antioxidant, oxidant, mechanism, mechanism of action and adults.

2.2 Review of Empirical Studies
2.2.1 Minor Neurovascular Events
We will define minor neurovascular events as a moderate to high-risk transient
ischemic attack (TIA) and minor ischemic stroke. Specifically, a moderate to high-risk TIA
will be classified as an ABCD2 score of equal to or greater than 4. The ABCD2 7-scale
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system determines a patient’s risk of recurrent stroke (Appendix C). In one study, patients
with a high-risk TIA (ABCD2 ≥ 6) had an 8.1% 2-day risk and a 36-43% 90-day risk of a
recurrent stroke. Patients with a moderate risk TIA (ABCD2 = 4 or 5) had a 4.1% 2-day
risk and 19-24% 90-day recurrence risk. Patients with a low-risk TIA (ABCD2 = 0 to 3)
had a 1.0% risk and 0-7% 90-day recurrence risk.1,2 A study validated the scoring system
by using it across different independent groups of patients.1 Given the validity of the
scoring in the ability to predict increased risk of secondary stroke in patients with a
moderate to high-risk TIA and evidence suggesting that a higher ABCD2 score has a greater
likelihood of being a true TIA (not a misdiagnosis), we will include patients with a
moderate to high-risk TIA (ABCD2 ≥ 4).
A minor ischemic stroke will be defined as a National Institute of Health Stroke
Scale (NIHSS) score as less than or equal to 3. The NIHSS scoring is a 42-point scale
accounts for the level of consciousness, gaze ability, visual ability, facial paralysis,
extremity motor drift, lower limb ataxia, sensation, aphasia, dysarthria, and extinction
(Appendix E).3 However, there is controversy on whether a NIHSS score of 4 or 5 should
be classified as a minor stroke as well. The literature that has specifically looked at
clopidogrel and aspirin included patients with a minor ischemic stroke with a NIHSS of
less than or equal to 3 so we will use the same scoring to define our minor ischemic stroke
population.4,5
Patients with a minor neurovascular event are at high risk of a subsequent stroke
with sources demonstrating a recurrence risk ranging from 3-17% within the first 90 days
of the index event.4-10 It is estimated that 50% of those who have a recurrent stroke will
experience the event within weeks of the ischemic stroke with the risk decreasing and

11

remaining steady by 6 to 12 months after the primary event.5 The recurrent event often
leads to disability and can lead to death. Recurrent stroke events may occur with worsening
of the primary stroke through plaque formation and/or vasoconstriction causing ischemia
or a new atheroembolic, cardioembolic, or hemorrhagic stroke after resolution of the
primary stroke.11,12 Patients with a TIA or minor ischemic stroke with an identified
thrombotic etiology are given antiplatelet therapy to prevent a recurrent ischemic event.
This section will discuss the different regimens for preventing a secondary ischemic stroke.

2.2.2 Current Treatment of Minor Neurovascular Events
2.2.2.1 Aspirin + Clopidogrel

Figure 1: Proposed Alpha-Tocopherol Mechanism Adapted from Gkaliagkousi et al.13-20
AA: arachidonic acid; AC: adenylyl cyclase; ATP: adenosine triphosphate; Ca2+: Calcium; cAMP: cyclic
adenosine monophosphate; cGMP: cyclic guanosine monophosphate; COX-1: cyclooxygenase-1; DAG: 1,2diacylglycerol; eNOS: endothelial nitric oxide synthase; IP3: inositol 1,4,5-trisphosphate; NO: nitric oxide;
O2-: superoxide; ONOO-: peroxynitrite; P2Y12: adenosine diphosphate receptor; PKC: protein kinase c;
PLA2: phospholipase a2; PLCβ: phospholipase cβ; ROS: reactive oxygen species; TXA2: thromboxane 2.
Solid arrows indicate activation, dashes indicate inhibition.

This section will review the accepted dual-antiplatelet therapy (DAPT) of
clopidogrel and aspirin that is used to prevent recurrent strokes in patients with a moderate
12

to high-risk transient ischemic attack (TIA) or minor ischemic stroke. A multitude of
randomized controlled trials have assessed the efficacy of DAPT versus antiplatelet
monotherapy. DAPT has since become a widely accepted and recommended regimen to
prevent stroke recurrence for this patient population.21 The two pharmaceutical drugs are
thought to work synergistically to reduce platelet aggregation causing a reduction in stroke
recurrence risk compared to antiplatelet monotherapy.22,23
However, there is debate in the literature over the efficacy of DAPT compared to
antiplatelet monotherapy. The MATCH trial was a double-blinded, multi-center, placebocontrolled study that randomized patients over 40 years old with a recent ischemic stroke
or TIA and an additional vascular risk factor to receive an 18-month course of DAPT or
clopidogrel alone. There was no significant difference between DAPT and clopidogrel
alone (15.7% vs 16.7%, RR reduction 6.4%; 95% CI, -4.6 to 16.3). Notably, participants
in the DAPT group had significantly more life-threatening bleeds than participants who
received only clopidogrel (2.6% vs 1.3%; absolute risk increase 1.3%, 95% CI, 0.6 to
1.9).24 It is important to note that the antiplatelet therapy was given for a course of 18
months but time to event analysis was not performed to determine if the increased risk of
bleeding could be due to prolonged antiplatelet use. The trial also had a broad inclusion
criterion that allowed participants to join if they had an ischemic stroke or TIA in the past
3 months. While broad inclusion criteria tend to increase external validity and
generalizability, studies have shown that the risk of recurrent stroke is highest within 90
days of the index event.25 Additionally, trials have shown that DAPT should be given
within 12 to 24 hours of the event to have maximum benefit.4,5 Studies have also shown a
benefit of DAPT in patients with a TIA with an ABCD2 score of greater than or equal to 4
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or a minor ischemic stroke with a NIHSS score of less than or equal to 3.4,5,9 DAPT is not
the recommended treatment for cardioembolic strokes, minor TIA’s, moderate and severe
minor ischemic strokes.21
The CHARISMA trial, a multi-center, double-blinded, placebo-controlled study,
randomized 15,603 participants, over the age of 45 years with risk factors for
atherothrombotic events, such as diabetes, smoking, coronary disease, and cerebrovascular
disease, to receive DAPT of clopidogrel and aspirin or aspirin alone for a median of 28
months. There was no significant difference in severe bleeding (RR, 1.25; 95% CI, 0.97 to
1.61; P=0.09) or in intracranial hemorrhage (RR, 0.96; 95% CI, 0.56 to 1.65; P=0.89), or
in the composite of myocardial infarctions, strokes, or mortality from cardiovascular causes
(RR, 0.93; 95% CI, 0.83 to 1.05; P= 0.22) between the two groups. Notably, participants
in the DAPT group had a significantly greater risk of developing moderate bleeding (RR,
1.62; 95% CI, 1.27 to 2.08; P<0.001) but a lower risk of having a non-fatal stroke (RR,
0.03; 95% CI, 0.64 to 0.98; P=0.03) or hospitalization from unstable angina, TIA, or
revascularization (RR, 0.90; 95% CI, 0.82 to 0.98; P=0.02) compared to participants taking
aspirin alone. Only 37% of participants in each group had a history of a stroke or TIA. No
subgroup analysis was performed for these participants.26 Neither the MATCH nor the
CHARISMA trial fully captured our target population. For the purpose of this study, we
will focus specifically on the literature that investigated DAPT in patients with minor
ischemic strokes and TIA’s as it has shown to be more efficacious in reducing stroke
recurrence compared to antiplatelet monotherapy.
The POINT study was a multi-center, randomized, double-blinded, placebocontrolled international trial that randomized 4,881 patients over 18 years old with a minor
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ischemic stroke (NIHSS  3) or moderate to high-risk TIA (ABCD2  4) within 12 hours
of symptom onset to receive either a 90-day course of DAPT of clopidogrel and aspirin or
aspirin alone with placebo tablets. The study found that patients who received DAPT had
a significantly lower risk of having major ischemic events (ischemic stroke, myocardial
infarction, or death from an ischemic vascular event) at 90 days compared to patients taking
aspirin alone (5% vs 6.5%; HR, 0.75; 95% CI, 0.59 to 0.95; P=0.02). Most ischemic events
occurred during the first week after the index event. Patients in the DAPT group had a
significantly greater risk of developing a major hemorrhage compared to patients who
received aspirin alone (0.9% vs 0.4%; HR, 2.32; 95% CI, 1.10 to 4.87; P=0.02). However,
there was no significant difference in death from hemorrhagic etiology in either group
(0.1% vs 0.1%). The study had a large sample size, randomized the participants, and
blinded both participants and researchers. This increases the internal validity and thus
strengthens the findings between DAPT and aspirin alone. The trial also increased the
external validity of the trial by including multiple international centers, thus enhancing the
generalizability of the trial.
The CHANCE trial, similarly, sought to determine the efficacy of short-term DAPT
of clopidogrel and aspirin followed by clopidogrel alone to prevent secondary ischemic
strokes in patients in China with a moderate to high-risk TIA or minor ischemic stroke.
Participants that met the eligibility criteria within 24 hours of their index event were
randomized to either receive a 21-day course of DAPT followed by clopidogrel alone from
day 22 to day 90 or aspirin plus placebo tablets for the full 90 days. 8.2% of participants
that received DAPT had a stroke (ischemic or hemorrhagic) by day 90 while 11.7% of
participants in the aspirin alone group had a stroke (ischemic or hemorrhagic) by day 90
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(HR, 0.68; 95% CI, 0.57 to 0.81; p < 0.001). More specifically, ischemic stroke occurred
in 7.9% in the DAPT group vs 11.4% in the aspirin alone group (HR, 0.67; 95% CI, 0.56
to 0.81; p < 0.001). In addition, hemorrhagic stroke occurred in 0.3% of participants in
each group (P=0.93) and moderate or severe hemorrhaging, as defined by the GUSTO
criteria (Table 4) occurred in 0.3% of participants in each group P = 0.73). There was a
trend in overall bleeding in the DAPT group, however this was not significant when
compared to the aspirin alone group, unlike the finding in the POINT trial.4,5 It is important
to note that although this trial was large, involving 5,170 patients from 114 centers, it was
specific towards patients in China, decreasing external validity.5 However, similar trials
investigating DAPT, including the POINT trial included the US, the CARESS trial done in
Europe, and the CLAIR trial done in Asia, all support the regimen’s greater efficacy in
reducing stroke recurrence, ischemic in particular, compared to aspirin alone.4,27,28 Given
the large sample size in the CHANCE trial and equal risk of developing moderate to severe
hemorrhage and hemorrhagic stroke between groups (0.3% vs 0.3%, p=0.73), it was
accepted into the guidelines for high-risk TIA/minor ischemic stroke treatment guidelines
by the American Heart Association.5,21
A meta-analysis that included five randomized controlled trials, including the
POINT, CHANCE, and CARESS trial recently described, found that short term DAPT of
aspirin and clopidogrel for 1 month or less significantly reduced the risk of recurrent
ischemic stroke (RR, 0.53; 95% CI, 0.27-0.78) and major cardiovascular events (RR, 0.72;
05%CI, 0.58-0.90) and did not increase the risk of major bleeding (RR, 1.82; 95% CI, 1.362.56) compared to aspirin alone. Similarly, DAPT given for 1 to 3 months (intermediate
term) significantly reduced the risk of recurrent ischemic stroke (RR, 0.72; 95% CI, 0.58-
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0.90) and cardiovascular events (RR, 0.76; 95% CI, 0.61-0.94). However, participants
given DAPT for the intermediate term had an increased risk of major bleeding events
compared to participants who received DAPT for the short term (RR, 2.58; 95% CI, 1.195.60). Participants who took DAPT for the long-term (over 3 months) had no significant
reduction in the risk of recurrent ischemic stroke (RR, 0.81; 95% CI, 0.63-1.04) or in
adverse cardiovascular events (RR, 0.87; 95% CI, 0.71-1.07) and showed a significantly
increased risk of major bleeding compared to participants who received DAPT for the short
term (RR, 1.82; 95% CI, 0.91-3.62).29 The majority of the participants that were included
in this study had a minor ischemic stroke and TIA patients. A couple of studies included
ischemic stroke patients were specific to lacunar strokes.30,31 The studies also varied on the
dosing of both clopidogrel and aspirin, which could have altered the meta-analysis results.
When looking specifically at moderate to high-risk TIA and minor ischemic stroke
patients, however, a multitude of studies have found a benefit to using DAPT, specifically
clopidogrel and aspirin, to reduce the risk of developing a recurrent ischemic
stroke.4,5,27,29,31 However, studies have varied in their length of onset to treatment, duration
of the DAPT and dosing. This variability could explain the argument regarding dual
antiplatelet therapy versus antiplatelet monotherapy when balancing ischemic stroke
recurrence and hemorrhaging.

2.2.2.2 Other Treatments
Aspirin + Ticagrelor
Trials have been exploring new secondary prevention strategies to reduce stroke
recurrence in patients with a moderate to high-risk transient ischemic attack (TIA) or minor
ischemic stroke compared to other treatments. In an international double-blinded
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controlled trial, patients with a moderate to high-risk TIA (ABCD2  4) or mild to moderate
ischemic stroke (NIHSS  5) were randomized within 24 hours of the index event to receive
a 90-day course of either ticagrelor, an antiplatelet agent, or aspirin. There was no
significant difference in stroke occurrence, myocardial infarction, or death within 90 days
in patients who took ticagrelor plus aspirin versus aspirin alone (6.7% vs 7.5%, HR, 0.89,
95% CI, 0.78 to 1.01, P = 0.07). Secondary analysis found no significant difference in
ischemic stroke between the two groups (5.8% vs 6.7%, HR, 0.87, 95% CI, 0.76 to 1.00).32
A similar international trial, double-blinded trial, patients with a high-risk TIA (ABCD2 
6) or minor to moderate ischemic stroke (NIHSS  5) were randomized within 24 hours of
the index event to receive a 30-day regimen of either ticagrelor plus aspirin or aspirin plus
placebo. There was a 5.5% chance of stroke or death within 30 days and 6.6% chance in
the aspirin alone group (HR, 0.83; 95% CI, 0.71 to 0.96; P = 0.02). Specifically, ischemic
stroke occurred in 5.0% in the ticagrelor-aspirin group and 6.3% in the aspirin group (HR,
0.79; 95% CI, 0.68 to 0.93; P = 0.004). Significantly more participants experienced severe
bleeding in the ticagrelor plus aspirin group than the participants in the aspirin alone group
(0.5% vs 0.1%, P=0.001).9 Although, there may be a decrease in stroke recurrence in the
ticagrelor-aspirin group within 30 days of the primary event, the trial did not fully capture
the high risk of recurrent strokes that exist within the full 90 days. Further investigation is
needed in the efficacy of ticagrelor and its potential role in dual antiplatelet therapy for the
full 90 days and should be compared to the current standard of clopidogrel and aspirin.

Aspirin + Dipyridamole
Another potential regimen to prevent stroke recurrence is aspirin plus
dipyridamole, an antiplatelet agent. In one study, participants with an ischemic stroke were
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randomized to receive either aspirin plus dipyridamole or clopidogrel alone. There was a
lower risk of mortality and subsequent stroke or myocardial infarction events within 90
days in the aspirin plus dipyridamole group (HR, 0.62, 0.43 to 0.91; HR, 0.70, 0.52 to
0.94).33 However, a different study found that patients taking aspirin plus dipyridamole had
similar rates of recurrent strokes, compared to patients taking clopidogrel alone (9.0% vs
8.8%, respectively, HR, 1.01, 95% CI, 0.92 to 1.11). The international, double-blinded,
randomized trial involved 20,333 participants who had an ischemic stroke, defined by focal
neurological symptoms lasting over 24 hours or evidence of an infarction on imaging, that
were prescribed either 25mg aspirin plus 200mg extended-release dipyridamole twice daily
or 75mg clopidogrel daily for 2.5 years. Neither study mentioned represented patients with
a transient ischemic attack and did not specify the severity of the ischemic stroke patients,
decreasing the external validity of the trial.33,34 Despite the regimen’s possible role in stroke
recurrence, multiple studies have shown that almost half of patients on dipyridamole had a
headache that resulted in a significant number of patients to discontinue the drug.34-36

2.2.3 Vitamin E Alpha-Tocopherol as a Potential Treatment
Vitamin E is a collection of fat-soluble molecules known as tocopherols and
tocotrienols. Alpha-tocopherol, in particular, is the most widely available and studied
component of vitamin E.37,38 This section will discuss the different proposed mechanisms
of vitamin E alpha-tocopherol including inhibition of platelet aggregation, potentiation of
aspirin, and reduction in oxidative stress. The mechanisms suggest a possible role in
reducing the incidence of stroke recurrence in patients with a high-risk transient ischemic
attack (TIA) or minor ischemic stroke.

19

2.2.3.1 Antiplatelet Properties
Vitamin E alpha-tocopherol (AT) has been shown to inhibit protein kinase C
(PKC), a platelet aggregate regulator, leading to an increase in nitric oxide (NO), decrease
in superoxide, and decrease in lipid peroxidation.18,39-43 An increase in platelet NO leads to
an increase in cyclic guanosine monophosphate (cGMP). cGMP activates cGMPdependent protein kinase (PKG) ultimately leading to inhibition of platelet aggregation.44,45
The decrease in superoxide and lipid peroxidation contribute to AT’s antioxidant properties
discussed later in this section.
Mice fed a high vitamin E diet for a mean of 15 days had significantly less platelet
aggregation and a longer time to thrombus formation compared to mice fed a regular diet
(P<0.05).46 Similarly, Li et al. found a significantly lower platelet count in mice that
received 8-weeks of either low dose vitamin E supplements (P<0.01) or high dose vitamin
E supplements (P<0.01) compared to mice who received placebo. There was a positive
dose effect relationship in the vitamin E alpha-tocopherol dose and platelet count.47
In a study, human platelets were incubated with different alpha-tocopherol and
found a significant decrease in adenosine diphosphate (ADP)-induced platelet aggregation
compared to the control (P<0.05). In addition, there was a significant decrease in lipid
peroxidation products an increase in NO compared to the control.47 ADP is a platelet
aggregation activator that is also inhibited by clopidogrel as seen in Figure 1.48 In another
study, it was found that peripheral blood from healthy volunteers incubated with vitamin
E had significantly less platelet aggregation when induced with Phorbol 12-myristate 13acetate (PMA), a PKC activator, compared to control peripheral blood that was induced
with PMA (P<0.05).49 Another study isolated platelet’s from human’s plasma and
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significant reduction in platelet aggregation when infused with alpha-tocopherol compared
to the vehicle of 5% ethanol (r = -0.78; P < 0.02). To determine the mechanism of the
alpha-tocopherol, the study utilized PKC-dependent and independent platelet agonists.
Alpha-tocopherol treated platelets inhibited PMA-induced phosphorylation of 47-kD
proteins, substrates of the PKC. In the same study, patients were randomized to alphatocopherol supplements of a dose ranging from 400, 800, or 1200IU/d for 14 days. Blood
samples were then obtained by the participants. PKC-dependent agonist phorbol 12myristate 13-acetate (PMA) and alpha-tocopherol supplementation at all doses
significantly has less platelet aggregation compared to pre-supplementation baseline (r
=.67; P<0.01). While the findings are significant, it is notable that the study only included
15 participants, decreasing the internal validity of the trial.40
Similar findings have been seen in other trials. Participants who were supplemented
with 400IU alpha-tocopherol daily for 14 days had a significant increase in NO production
(P<0.05) and less ROS (P<0.05) compared to the control. The study also found that through
immunoprecipitation, platelets incubated with alpha-tocopherol did not have PKCdependent eNOS phosphorylation, suggesting that alpha-tocopherol increases NO release
through a PKC dependent mechanism.18 This trial also had a very small sample size of 5
participants, decreasing the internal validity of the results. However, given the results of
the aforementioned studies, it may be proposed that alpha-tocopherol inhibits platelet
aggregation through the PKC pathway, as demonstrated in Figure 1.
The antiplatelet mechanism of alpha-tocopherol has been supported clinically as well.
Notably in the ATBC study, healthy men who were given 50mg (approximately 75IU) of
alpha-tocopherol had a significantly lower risk of cerebral infarctions and no increased risk
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of subarachnoid hemorrhages compared to those taking placebo (P=0.035; P=0.07).50
Glynn et al. randomized participants over the age of 45 years old to receive 600IU of
vitamin E or placebo for a median of 10.2 years. People in the vitamin E group had a
significantly lower risk of developing a venous thromboembolism (VTE) (relative hazard,
0.73; 95% CI, 0.66 to 0.94; P=0.010). The risk is lowered in those who had a history of a
VTE (relative hazard, 0.56; 95% CI, 0.31 to 1.00; P=0.048), no history of a VTE (relative
hazard, 0.82; 95% CI, 0.68 to 0.99; P=0.048), and a history of a factor V Leiden or
prothrombin mutation (relative hazard, 0.51; 95% CI, 0.30 to 0.87; P=0.014).51 These
results further support the antiplatelet properties of vitamin E.

2.2.3.2 Aspirin Potentiation
In addition to the nitric oxide (NO) increase, research also suggests that alphatocopherol increases prostacyclin synthesis through inhibition of phospholipase A2 and
cyclooxygenase (COX) by a similar mechanism as aspirin as seen in Figure 1. As a result,
when vitamin E alpha-tocopherol is used in combination with aspirin, the antiplatelet
effects are potentiated resulting in a significant decrease in platelet aggregation.13,14,17,52
Gonzalez-Correa et al. found that rats treated with vitamin E alone had significantly
less platelet aggregation than saline treated rats (P<0.001). There was significantly less
platelet aggregation in the rats treated with aspirin and alpha-tocopherol compared to the
control/nondiabetic rats, the saline treated diabetic rats, the aspirin treated diabetic rats, and
the alpha-tocopherol treated diabetic rats (P<0.05; P<0.0001; P=0.015; P=0.002,
respectively). The combination of aspirin and alpha-tocopherol had greater inhibition of
thromboxane production compared to alpha-tocopherol alone (P=0.038). The combination
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also potentiated prostacyclin production compared to alpha-tocopherol alone (P<0.0001)
and aspirin alone (P<0.0001). Aspirin plus alpha-tocopherol also potentiated NO compared
to alpha-tocopherol alone and aspirin alone (P=0.020, P=0.011, respectively). The study
has limited external validity given a population of strictly type 1 diabetic rats. Of note,
saline treated diabetic rats had significantly more platelet aggregation than the control
nondiabetic rats (P<0.05). However, the aspirin and vitamin E alpha-tocopherol group did
show significantly less platelet aggregation than the control non-diabetic rats (P<0.05). The
study also supports the mechanism of alpha-tocopherol’s inhibition of thromboxane,
increase in prostacyclin, increase in NO, and overall inhibition of platelet aggregation.
These findings suggest vitamin E antiplatelet properties that synergistically work with
aspirin and potentiate platelet aggregation inhibition.17
Whole blood from healthy men was mixed with either aspirin alone or aspirin and
alpha-tocopherol. NO was significantly higher in whole blood treated with both aspirin and
alpha-tocopherol compared to aspirin alone resulting in less platelet aggregation (P<0.05).
Vitamin E spared (at low doses) and significantly increased prostacyclin levels (at high
doses) while aspirin significantly decreased prostacyclin synthesis (P<0.05) compared to
the control. When alpha-tocopherol and aspirin were used together, there was significantly
less prostacyclin inhibition compared to aspirin alone (IC50 12.92 ± 1.10uM vs IC50 1.81 ±
0.15uM; P<0.05).14 In another study, human platelets were incubated with vitamin E and
both the low dose, 50uM, (P<0.001) and high dose, 100uM, (P<0.001) inhibited platelet
adhesion compared to platelets treated with aspirin alone. Because platelet activation was
inhibited using collagen, the component that is exposed during endothelial damage thus
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leading to recruitment of platelets, vitamin E has again shown to potentiate aspirin’s
inhibition of platelet aggregation.52
In one double-blinded, placebo-controlled trial 100 patients, over 18 years old, with
a minor stroke, reversible ischemic neurologic deficit, retinal ischemic event, or TIA within
8 weeks from enrollment were randomized to a 2-year course of either aspirin plus alphatocopherol or aspirin alone. Patients who received aspirin plus alpha-tocopherol had a
significantly lower risk of recurrent stroke (hemorrhagic or ischemic) compared to patient’s
who took aspirin alone (5.7% vs 12.5%, P<0.05). There was no significant difference in
hemorrhagic strokes between the two groups. Unfortunately, the trial has many issues.
First, the study was not completed at the time of publication. At the time only 33 patients
had reached a termination point and 16 patients had completed the 2-year study. Therefore,
the analysis on recurrent stroke was only performed on about half of the total sample size
of 100 patients. No follow-up study has been found for the complete study. So, while the
preliminary results suggest a significant difference in stroke recurrence and platelet
adhesion, the trial’s limitations must be considered.53 Notably, studies have not
investigated short-term administration of vitamin E alpha-tocopherol nor in combination
with antiplatelet drugs. Given the gap in the literature, this study will investigate further on
the efficacy of alpha-tocopherol plus antiplatelet drugs on stroke recurrence in patients with
high-risk TIA or minor ischemic stroke. This gap and study’s limitations further emphasize
the need for this trial.
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2.2.3.3 Antioxidant Properties
Reactive oxygen species (ROS) are free radicals that damage cell membranes through
lipid peroxidation. Lipid peroxidation is the process in which free radicals remove electrons
from lipids that construct cell membranes. Removal of electrons cause disrupted, unstable
cellular membranes that lead to cell death.54 Under standard conditions, ROS is produced
through aerobic metabolism but is scavenged by endogenous antioxidants such as
glutathione peroxidase and vitamin E thus preventing cell damage. Specifically, alphatocopherol is a fat-soluble antioxidant that donates a hydrogen to inactivate free radicals,
reducing lipid peroxidation and thus maintaining cellular membrane integrity.15,20 During
an ischemic stroke, there is excessive metabolic production of ROS that are not scavenged
causing neuronal cell death and possibly disability.55 Given alpha-tocopherol’s ability to
bind to free radicals, supplements may have a potential role in reducing cell death and
ultimately, reducing function deficit post-infarction.17,56
In an animal trial, transient focal cerebral ischemia for 90 minutes was induced in
rats. Rats who were pre-treated with alpha-tocopherol had significantly less brain edema
(P < 0.001, 80.1 ± 0.32% vs 83.8 ± 0.11) and less disruption of the blood brain barrier (as
seen by less Evans Blue leakage) (P < 0.001, 6.66 ± 0.87 µg/g vs 14.58 ± 1.29) compared
to the control group. In addition, the alpha-tocopherol group had a significantly reduced
concentration of malondialdehyde, an oxidative stress marker and marker of lipid
peroxidation, (P < 0.001, 26.84 ± 4.79 nmol/mg vs 63.57 ± 5.42 nmol/mg) and elevated
concentration of glutathione, an endogenous antioxidant, (P < 0.01, 10.17 ± 0.83 mmol/mg
vs 5.86 ± 0.31 mmol/mg) compared to the control group post-ischemia. The alphatocopherol group also had significantly diminished cerebral lesion volumes (P <0.01, 241
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± 29 mm3 vs 422 ± 41mm3) and less severe motor disabilities (as measured by the
neurological deficit score) (P <0.05, 1.75 ± 0.25 vs 4 ± 0.5) compared to the control group.
These findings imply that pre-treatment with alpha-tocopherol may protect the brain from
edema and disruption of the blood brain barrier through an antioxidant mechanism by
reducing oxidative stress and increasing endogenous antioxidants leading to less cerebral
death resulting in reduced disability severity compared to no pre-treatment.57
Numakawa et al. found that 24 hour pretreated cultured cortical neurons from rats
either alpha-tocopherol (P<0.001), alpha-tocotrienol (P<0.001), gamma-tocopherol
(P<0.01), and gamma-tocotrienol (P<0.001) had significantly less neuronal death than the
vehicle-treated neurons after H2O2 administration.55 Notably, both animal studies
mentioned have limited external validity as they are specific to rats. However, the study
may improve our understanding of mechanism of vitamin E and its potential role in
reducing oxidative damage from ischemic stress. Research has shown that pre-treatment
with vitamin E may be protective against cell damage and death if the animal undergoes
an ischemic event.55,57 Therefore, vitamin E may not only help reduce the incidence of
stroke but if a stroke occurs, it may reduce ischemic damage thus reducing the degree of
disability if a recurrent ischemic stroke were to occur.
Unfortunately,

human

trials

investigating

alpha-tocopherol’s

antioxidant

mechanism post-cerebral ischemia is limited. In one trial patients with an acute ischemic
stroke were randomized to receive either 727 mg (800IU) alpha-tocopherol and 500mg of
vitamin C or no treatment for 14 days. The study reproduced similar findings to the
aforementioned animal studies, showing a reduction in the change in malondialdehyde
concentration from day 0 to day 7 in patients who received vitamin E and C compared to
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the control group (P<0.01, median -0.13umol/l vs 0.03, respectively). Patients treated with
vitamin E and C also had a significantly greater median change from day 0 to day 7 of total
antioxidant capacity compared to the control group (P<0.05, median 0.09mmol/l vs 0.01,
respectively). The study had a small sample size of 48 participants and was performed at a
single hospital in England thus limiting the external validity of the trial’s findings. The trial
also combined vitamin E and C supplements and did not compare the effects of the drugs
separately reducing the internal validity.58 Despite the study design of the aforementioned
study, other human trials investigating other disorders have demonstrated that vitamin E
alpha-tocopherol supplements at doses as low as 100IU is associated with a significantly
lower malondialdehyde concentration and increased glutathione concentration, further
supporting the vitamin E alpha-tocopherol antioxidant mechanism in humans.59-61
The literature discussed has shown that alpha-tocopherol scavenges free radicals,
increases endogenous antioxidants, reduces brain edema, protects the blood brain barrier,
and ultimately, reduces disability severity. To further investigate vitamin E alphatocopherols potential antioxidant effects, we will measure degree of disability using the
modified Rankin Scale (mRS) at baseline and at day 90 and compare the mean change in
mRS between groups. We will also compare mean mRS scores between groups in patients
who had a recurrent stroke (ischemic or hemorrhagic) to investigate the relationship
between disability in those were pre-treated with and without alpha-tocopherol.

2.3 Identifying Potential Confounding Variables
There are several potential confounding variables that may influence stroke
recurrence that need to be accounted for in this trial. Previous randomized controlled trials
have investigated potential confounding variables and their potential effect on stroke

27

recurrence. A 2017 study performed a subgroup analysis of the CHANCE trial to determine
potential risk factors associated with recurrent stroke in patients with dual antiplatelet
therapy (DAPT). The study found that patients with a history of hypertension (P<0.009),
history of smoking (P<0.02), higher body mass index (P<0.02), less likely to have a lipid
lowering agent (P<0.01), and a baseline NIHSS score of 2 (HR 2.12; 95% CI, 1.07 to 4.21)
or 3 (HR 4.11; 2.05 to 8.22) compared to those who did not have a stroke of DAPT.62 We
will also control for diabetes mellitus and co-existing cardiovascular diseases has they have
been shown to place patients with a transient ischemic attack (TIA) or minor ischemic
stroke at an increased risk for a recurrent stroke.10,63,64
In addition, age and race have been associated with an increased risk of stroke
recurrence. We will account for age given research has demonstrated that those over the
age of 60 years who have had a minor neurovascular event are at an increased risk of
developing a recurrent stroke compared to those younger than 60 years old.1,2 In addition,
a study suggests that Black individuals at higher risk of early stroke recurrence compared
to White individuals (HR, 1.6; 95% CI, 1.1-2.3).65
Although there is no difference in recurrent stroke in patients with a TIA or minor
stroke between men and women as demonstrated by multiple studies, women score worse
on the modified-Rankin Scale (mRS) 1 to 6 months after a TIA or ischemic stroke,
implying women may be more disabled after the event.66 Therefore, we will account for
gender given its potential influence on disability, one of our secondary outcomes. In
addition, time from initial presentation to randomization, and number of TIA and minor
ischemic stroke patients. To control for potential confounders, we will first randomize the
patients and then perform a secondary analysis utilizing multiple logistic regression.
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2.4 Review of Relevant Methods
2.4.1 Study Design
The trial will be a prospective, multi-center, randomized, double-blinded, placebocontrolled trial performed to test the efficacy of vitamin E alpha-tocopherol in addition to
clopidogrel and aspirin versus clopidogrel and aspirin alone in patients who have had a
minor ischemic stroke or transient ischemic attack (TIA) who are at risk for a recurrent
stroke. Similar to the trials that have investigated new treatment regimens for minor
ischemic stroke and TIA patients, such as the CHANCE and POINT trial, this trial will
mimic their study’s design.4,5 We will compare our intervention to the standard treatment
to determine the efficacy of the new regimen.
Multiple stroke centers will be selected using the NIH Stroke Net to increase the
generalizability and reduce selection bias.67 Participants will undergo the typical
neurological work-up according to the stroke center’s protocol. Once the patient meets the
eligibility criteria and is enrolled into the study, they must obtain a magnetic resonance
imaging (MRI) or computed tomography (CT), if not done already, within 24 hours of the
index event with no evidence of hemorrhage or nonischemic cause of a neurological deficit
as done in previous trials.4,5 Similar to the POINT trial, we will use an interactive,
computer-based system, WebDCU, that will randomize patients in a 1:1 ratio to receive
either DAPT plus vitamin E alpha-tocopherol supplements or DAPT plus placebo.4 Given
current guidelines and results from the CHANCE trial, both groups will receive a 21-day
course of both clopidogrel and aspirin followed by clopidogrel alone for the remainder of
the 90 days to reduce the incidence of serious bleeding.5,21 Patients will receive either
vitamin E alpha-tocopherol or placebo tablets for the full 90 days. Both participants and
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researchers will be blinded to the intervention with the use of the assignment of a
randomized identification number and the use of placebo tablets that will be identical to
the alpha-tocopherol supplements.

2.4.2 Control and Interventional Groups
Participants will be randomized to either the control group, which will be dual
antiplatelet therapy (DAPT) of clopidogrel and aspirin plus placebo tablets, or the
interventional group, which will be DAPT plus 200IU vitamin E alpha-tocopherol
supplements. Several studies have shown that DAPT is superior to other treatment
regimens in reducing stroke recurrence in patients with a history of a high-risk transient
ischemic attack (TIA) or minor ischemic stroke.4,5 We will mimic the procedures of the
CHANCE trial and administer loading doses of 300mg oral clopidogrel and open label
72mg to 300mg oral aspirin within 12 hours of the index event to both groups. Both groups
will then receive 75mg aspirin per day from day 2 to day 21 and 75mg clopidogrel per day
from day 2 to day 90.

5

In addition, the control group will receive a 90-day course of

placebo supplements that resemble and taste like the vitamin E alpha-tocopherol
supplements.
The interventional group will receive 200IU of vitamin E alpha-tocopherol from
day 1 to day 90 in addition to the DAPT. It has not escaped us that 400IU is the most
widely studied dose in vitamin E alpha-tocopherol trials. Controversy remains with studies
suggesting no benefit of low dose 200IU alpha-tocopherol and no benefit of alphatocopherol at higher doses platelets and oxidative stress.68,69 Studies have shown that
vitamin E alpha-tocopherol increases nitric oxide and reduces platelet aggregation at doses
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from 75IU/day to 200IU/day.70-73 Given the controversial research, risk of bleeding, and
new antiplatelet regimen, we will utilize 200IU of alpha-tocopherol for 90 days. we
hypothesize that this dose will be sufficient to potentiate aspirin in the first 30 days as well
as provide antiplatelet and antioxidant characteristics in combination with clopidogrel to
reduce the incidence of stroke recurrence within 90 days of the index event.

2.4.3 Inclusion and Exclusion Criteria
To determine the inclusion and exclusion criteria, we analyzed literature that
studied the use of clopidogrel, aspirin, and alpha-tocopherol. By basing our inclusion and
exclusion criteria on studies of all three drugs, we will encapsulate the full and adequate
population that capture the population that may benefit from the intervention while
minimizing adverse events. Specifically, we will be modeling our inclusion and exclusion
criteria off of the CHANCE trial, POINT trial, and Leppalla et al study.4,5,50 Of note, we
will exclude patients with a creatinine of greater than 2mg/dl or with hepatic insufficiency
given hepatic metabolism and partial renal excretion of vitamin E, aspirin, and
clopidogrel.74-76 The full inclusion and exclusion criteria can be found in Table 1.

2.3.4 Primary Outcome
The primary outcome that we will be measuring is stroke recurrence (ischemic and
hemorrhagic) within 90 days of the index event. This outcome has been the main measure
when trialing new therapies for a primary neurovascular event and will determine the
effectiveness of the treatment regimen.5,27,30,77,78 Similar to the CHANCE trial, ischemic
stroke will be defined as a sudden onset of new focal neurological deficit, evidence on
imaging of an infarction for 24 hours or more, quick worsening of an existing focal
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neurological symptom or sign, and not due to a nonischemic cause. Hemorrhagic stroke
will be defined as blood in the parenchyma or subarachnoid space as confirmed on imaging
with associated neurological signs or symptoms.5 Further analysis will be performed to
analyze the incidence of ischemic stroke recurrence and hemorrhagic occurrence separately
between the two groups. Though studies have measured this outcome as a time to
recurrence, we will first measure it as a proportion.4,5,34 Secondary analysis will be
performed to measure time to first recurrence using hazards ratio. This is further explained
in section 3.10.

2.3.5 Secondary Outcomes
We will measure myocardial infarction (MI), all-cause mortality, degree of
disability, and day 90 serum alpha-tocopherol levels as secondary outcomes. Previous
studies have measured myocardial infarction as a primary or secondary outcome.4,5,79 A
systemic review that analyzed 39 studies, including 65,996 patients, found that the annual
risk for MI’s was 2.2%.80 In addition, a subgroup analysis of the CHANCE trial and found
that 1.7% of the participants who were prescribed DAPT had a MI within 90 days of the
initial event.62 The international POINT trial found only 0.4% of patients on DAPT had a
MI within 90 days of the index event.4 Given the low percentage but its ischemic etiology
and vitamin E’s potential antiplatelet role, MI will be measured as a secondary outcome.
In addition, similar other studies, this trial will include 90-day all-cause mortality as a
secondary outcome.4,5,30
Other secondary outcomes include degree of disability (mRS) and serum alphatocopherol levels. Degree of disability at 90 days will be measured using the modified
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Rankin, a 6-leveled scale that evaluates recovery from a stroke and the patient’s level of
disability, as seen in similar trials.5,81,82 A literature review analyzed 224 articles and found
evidence to suggest that the mRS is reliable with strong test-re-test reliability (K=0.81 to
0.95) and is valid when comparing the mRS score with the stroke type, lesion size,
perfusion and impairment.83 We will assess the relationship between the degree of
disability and the administration of vitamin E supplements in addition to DAPT. Multiple
studies have shown that DAPT improves functional outcome, as measured by degree of
disability, at 90 days when compared to aspirin.4,5,81 Lastly, we will measure a fasting
serum alpha-tocopherol level at the end of the 90 days and the mean serum alphatocopherol level will be compared between groups. By doing so, we will determine if there
is a significant difference in serum alpha-tocopherol and if a significantly higher or lower
serum level can be associated with the primary or secondary outcomes as seen in other
studies.53,84

2.4.6 Safety Outcome
A meta-analysis, including 8 primary and secondary prevention trials, states that
vitamin E increases the risk of hemorrhagic stroke (pooled relative risk 1.22; 95% CI, 1.00
to 1.48; P=0.045) and reduces ischemic stroke risk by 10% (pooled relative risk 0.90; 95%
CI, 0.82 to 0.99; P=0.02). The study suggests a significant relationship between
hemorrhagic stroke and vitamin E; however, the confidence interval of the study includes
1.00 and therefore, there may in fact be no relationship.85 A 2020 meta-analysis including
18 randomized controlled trials, investigating primary and secondary prevention of stroke
with the use of vitamin E supplements, demonstrated a significant risk reduction in
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ischemic stroke (RR=0.92, 95% CI 0.85–0.99, p=0.04) but not in hemorrhagic stroke
(RR=1.17, 95% CI 0.98–1.39, p=0.08). There was no significant difference in total stroke
(RR= 0.98,95% CI 0.92–1.04, p=0.57).86 Stroke was not the primary outcome in multiple
of the studies and the trial’s included also had varying populations with different comorbidities. Only half of the studies tested secondary prevention strategies for
cardiovascular disease and many did not examine bleeding risk. As a precaution given the
novel treatment and antiplatelet use, we will include hemorrhagic stroke in our primary
outcome (in addition to ischemic stroke) and measure bleeding as a safety outcome. In
addition, a data safety and review board will incrementally look at outcome data in order
to identify if there is a statistical safety concern and determine if the trial should be halted.
There was an increased risk in major bleeding in patients who had a minor ischemic
stroke or a high-risk transient ischemic attack (TIA) and received aspirin and clopidogrel
(DAPT) for 90 days compared to antiplatelet monotherapy of aspirin (0.9% vs 0.4%).4
However, when a 21-day course of DAPT is prescribed followed by clopidogrel alone for
the remainder of the 90 days, there was no significant increase in moderate or severe
bleeding events compared to aspirin alone (0.3% vs 0.3%).5 As a result, the latter trial had
a higher risk of secondary stroke of 8.2% compared to the first trial with a risk of 6.5%.4,5
We propose that patients take a 21-day course of clopidogrel and aspirin followed by
clopidogrel from day 22 to day 90. In addition, 200IU vitamin E alpha-tocopherol
supplements, a mild antiplatelet, for the entirety of the 90 days as described in Section
2.3.2. We will utilize the GUSTO criteria to define severe, moderate, and mild bleeding as
used by the CHANCE trial and as described in Section 3.8.

2.4.7 Sample Size Calculation
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Our sample size was calculated using randomized controlled trials addressing
stroke recurrence (hemorrhagic and ischemic) within 90 days of randomization. In the
CHANCE trial, the recurrence risk for secondary stroke after a high-risk transient ischemic
attack (TIA) (ABCD2  4) or minor ischemic stroke (NIHSS  3) was 8.2% associated
with a 90-day course of clopidogrel and 21-day course of aspirin compared to 11.7%
recurrence risk with aspirin alone (HR 0.68, 95% CI, 0.57 to 0.81, p<0.001). In the study’s
interventional group, clopidogrel was given as a loading dose of 300mg on day 1 followed
by 75mg daily from day 2 to day 90. Aspirin was given as a loading dose with an open
label of 72mg to 300mg on day 1 followed by 75mg daily from day 2 to day 21. The
limitation to this study is that the population was confined to China, limiting the
generalizability of the study. Also, 6.4% of the sample size discontinued from the trial.
However, the study was a large sample of over 5,000 participants and accounted for a 5%
drop-out in its sample size. Because the study population and the interventional group in
the CHANCE trial closely resembles this proposed trial’s control group, the 8.2% recurrent
risk was used when calculating this study’s sample size.5
To estimate the rate difference we were limited, due to the lack of research, to a
small study that observed the relationship between the administration of aspirin and alp
and recurrent stroke in patients with a history of a TIA (ABCD2  4) or a minor ischemic
stroke (NIHSS  3) versus aspirin alone. 5.7% of patients who were given a 2-year regimen
of 400IU vitamin E alpha-tocopherol plus aspirin had a recurrent stroke (hemorrhagic or
ischemic) versus 12.5% in patients taking aspirin alone (p<0.05). A major limitation to this
study is its analysis of only 50% of its small sample size of 100 participants because the
trial was still ongoing and has not followed up with another publication with the full data.
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In addition, it prescribed 375mg of Aspirin for 2 years instead of the new standard of 90day course of 75mg clopidogrel with 21-day course of 75mg of aspirin. Given the
aforementioned study’s population and intervention, the addition of clopidogrel, and the
POINT and CHANCE trial suggesting a 1.5-3.5% rate difference, the incidence of 5%, to
create a 3.2% rate difference, was used when calculating the study’s sample size for this
proposed trial.4,5,53 When calculating our sample size, we used a two-tailed alpha of 0.05
and a power of 80% to detect a rate difference of 3.2%. We also took into account an 8%
withdrawal rate. Please see Chapter 3 for the calculation.

2.5 Conclusion
The literature previously described support the need for this randomized controlled
trial. The proposed mechanism of vitamin E alpha-tocopherol and studies on its effects on
platelet aggregation, aspirin potentiation, and antioxidant properties support vitamin E
alpha-tocopherol’s potential role in preventing stroke recurrence in patients with a minor
neurovascular event. However, the literature is limited in addressing this intervention in
combination with clopidogrel and aspirin in this high-risk population. This study aims to
fill this gap and improve clinical outcomes for patients with a moderate to high-risk TIA
or minor ischemic stroke.
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CHAPTER 3: METHODS
3.1 Study Design
The study will involve multiple stroke centers including multiple emergency
departments and neurology units that are responsible for discharging patients with a minor
neurovascular event and giving prescriptions for outpatient medications. We will evaluate
the effect of a 90-day regimen of 200IU vitamin E alpha-tocopherol supplements, in
addition to the standard treatment of clopidogrel and aspirin, on stroke recurrence among
patients who have had a moderate to high-risk TIA or a minor ischemic stroke. When a
patient arrives to a study trial center and are determined to have a minor neurovascular
event, they will be blindly randomized to the intervention or control group.
The primary null hypothesis of this randomized, double-blinded, multi-center,
placebo-controlled trial is that patients with a moderate to high-risk TIA (ABCD2  4) or
minor ischemic stroke (NIHSS  3) who receive a 90-day regimen of 200IU vitamin E
alpha-tocopherol in addition to the treatment of clopidogrel and aspirin will not have a
statistically significant difference in the proportion of stroke recurrence (hemorrhagic or
ischemic) within 90 days from the primary neurovascular event.

3.2 Study Sites, Population, & Sampling
The study population will include patients over the age of 18 years with a primary
moderate to high-risk transient ischemic attack (TIA) (ABCD2  4) or minor ischemic
stroke (NIHSS  3) who present within 12 hours to an emergency stroke center located
within a tertiary medical center. The stroke center must be certified by the Joint
Commission to contain the necessary training and resources for stroke patients. In

43

collaboration with the NIH Stroke Net, we will select stroke centers across the United
States to participate in this interventional trial. We plan to include at least 10 stroke centers
to recruit at least 2,002 participants over the course of a year. Each study site will have a
physician investigator and research assistant who will remain in contact with the site’s
emergency medicine physicians and neurologists who are primarily responsible for
diagnosing and treating stroke patients to ensure enrollment of eligible patients. A clinical
research coordinator (CRC) will also be put into place to oversee, direct and coordinate the
clinical trial, ensuring that the protocols are met at each center. The CRC will also be
responsible for ensuring resources are transported from the hub (Yale New Haven
Hospital) to the satellite medical centers. The full research proposal will be submitted to
the central Institutional Review Board (IRB) that is responsible for multi-center trials. Once
the central IRB has accepted our proposal, we will begin recruiting eligible participants.
Participants must be at least 18 years old and have either a TIA with an ABCD2
score of 4 or greater or a minor, nondisabling, ischemic stroke with a NIHSS score of 3 or
less at the time of randomization. Patients who experience a TIA must have resolution of
neurological symptoms at the time of randomization. A head computed tomography (CT)
scan, CT angiography, magnetic resonance imaging (MRI), or MR angiography scan must
be obtained and demonstrate that the neurological symptoms are NOT due to a hemorrhage
or another brain pathology such as a tumor or vascular malformation as recommended by
American Heart Association guidelines.1 If the inclusion and exclusion criteria are met, all
participants must sign and date a consent form (Appendix A) in order to be included and
randomized to the trial. Please see Table 1 for the extensive exclusion criteria and a review
of the inclusion criteria.
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Table 1. Inclusion and Exclusion Criteria
1.
2.
3.

4.

5.
6.

Inclusion Criteria
Age ≥ 18 years old
Acute, minor, nondisabling stroke with a
NIHSS ≤ 3 at time of randomization
TIA with resolution of symptoms by the time
of randomization and a moderate-high risk of
stroke recurrence as classified by an ABCD2
score ≥ 4
Head CT or MRI showing no evidence of a
hemorrhage or other brain pathology that could
contraindicate
treatment
or
explain
neurological deficits (i.e., tumor, vascular
malformation, abscess, multiple sclerosis)
Must be randomized within 12 hours of
symptom onset
Signed and dated informed consent

1.
2.
3.

4.
5.
6.
7.
8.
9.
10.
11.

12.
13.
14.
15.

16.
17.
18.
19.

Exclusion Criteria
Age ≤ 18 years old
TIA symptoms limited to isolated numbness, visual changes, or
dizziness/vertigo
Candidate for thrombolysis, endarterectomy, or endovascular
intervention as determined by providing physician (unless patient
refuses the intervention by time of randomization)
Received intravenous or intra-arterial thrombolysis within 1 week of
primary event
Major surgery within 3 months prior to the primary event
GI bleed within 3 months prior to primary event
Clear indication for anticoagulation therapy or anticipation to treat
during study period
Ischemic event due to angiography or surgery
Non-cardiovascular comorbidity with life expectancy of ≤ 3 months
Score of more than 2 on the modified Rankin scale immediately before
occurrence of the primary ischemic stroke or TIA
Contraindication to clopidogrel or aspirin (known allergy, serum Cr
>2 mg/dL, hepatic insufficiency, severe cardiac failure, hemostatic
disorder, systemic bleeding, history of thrombocytopenia or
neutropenia, current thrombocytopenia platelet count <100x10 9,
current neutropenia <1x109/l, history of drug-induced hematologic or
hepatic abnormalities)
Anticipated requirement for long-term non-study antiplatelets or
NSAIDs affecting function of platelets
Currently receiving an investigational therapy or treatment within the
last 7 days
Other neurological complications that complicate assessment of
outcomes
Premenopausal or postmenopausal women at risk for pregnancy
within 12 months of last menses without a negative pregnancy test or
without reliable contraception
Unwilling or unable to discontinue concomitant medications
Unavailable for follow-up
Missing signed and dated informed consent
No use of individual supplements of vitamin A, E or beta carotene for
more than once a week

3.3 Participant Confidentiality
This multi-center trial must be reviewed and approved by the Central Institutional
Review Board (central IRB) prior to study initiation. In addition, all research members
must be certified through the Health Insurance Portability and Accountability Act (HIPAA)
before recruitment begins. For patient privacy, patient records and data will be secured
through device encryption and password protected data. The information will only be
accessible to members of the research team. In addition, we will de-identify all participants
and utilize a computerized program that will randomize participants to identification
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numbers. After we complete data analyses, all participant data and information will be
properly disposed.
After the participant has met the inclusion and exclusion criteria, then he or she will
be required to complete written, informed consent (Appendix A). A research assistant at
each clinical site will explain the consent form and ensure that each participant has signed
and dated the form prior to randomization. The consent form will include a detailed
description of the trial, potential risks and benefits, economic considerations, and
confidentiality. The form will also state that participants have the ability to withdraw from
the trial at any point. Once written, informed consent is obtained, the participant will be
randomized into the trial.

3.4 Study Variables
The independent variable will be 200IU vitamin E alpha-tocopherol supplements
that will be delivered in oral capsules. The control variable will be oral placebo tablets that
will have the same packaging and be identical to the taste and appearance of the alphatocopherol supplements. The primary outcome will be stroke recurrence (hemorrhagic or
ischemic), including fatal and non-fatal events, within 90 days of randomization. An
ischemic stroke is defined as an acute, arterial block reducing or halting blood flow to the
brain resulting in focal symptoms. Hemorrhagic stroke is defined as extravasation of blood
into the parenchymal or subarachnoid space of the brain. The safety outcome will be
moderate and major bleeding as defined by the GUSTO criteria described in Table 4.
The secondary dependent variables that will be measured are degree of disability,
serum vitamin E alpha-tocopherol, proportion of myocardial infarction (MI), and
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proportion of all-cause mortality. Degree of disability will be measured in all participants
using the modified Rankin Scale (mRS) at the time of randomization and at the end of 90
days. Vitamin E alpha-tocopherol level is defined as the concentration of alpha-tocopherol
within the patient’s serum. The reference range for alpha-tocopherol is defined as 5.5-17.0
mg/L in people 18 years or older. MI, with or without coronary revascularization, will be
defined as myocardial necrosis with myocardial ischemia and we will use the Universal
Definition of Myocardial Infarction algorithm that accounts for cardiac biomarkers, EKG
abnormalities, imaging, pathology, and clinical setting.2 All-cause mortality will be defined
as all participant deaths that occur within 90 days of randomization.
Table 2. Baseline Characteristics Description and Analysis
Baseline Characteristics
Age
Female Sex
Body Mass Index
Race
Ischemic Heart Disease
Hypertension
Diabetes Mellitus
Smoking Pack Years
Clopidogrel Use at Presentation
Aspirin Use at Presentation
Time from Initial Presentation to Randomization
ABCD2 Score
NIHSS Score
TIA Subjects
Minor Ischemic Stroke Patients

Description
Measured in years
No./total No.(%)
Median (Range)
White, Black, Asian, Hispanic, Other (No./total No.(%))
No./total No.(%)
No./total No.(%)
No./total No.(%)
(# cigarettes per day) x (years smoked): Mean Pack Years ±
SD
No./total No.(%)
No./total No.(%)
Mean time (hrs) ± SD
Median (Range)
Median (Range)
No./total No.(%)
No./total No.(%)

Analysis
ANOVA
Chi-Square
ANOVA
Chi-Square
Chi-Square
Chi-Square
Chi-Square
ANOVA
Chi-Square
Chi-Square
ANOVA
ANOVA
ANOVA
Chi-Square
Chi-Square

Stroke recurrence within 90 days of the neurovascular event can be attributed to
many baseline characteristics and have the potential to impact the study groups. We will
control for many factors including age, gender, body mass index, race, known risk factors
(ischemic heart disease, hypertension, diabetes mellitus, smoking history), medication use
at presentation (aspirin, clopidogrel, multivitamin use), time from initial presentation to
randomization, neurovascular event (TIA vs minor ischemic stroke), and median
qualifying neurologic score (ABCD2, NIHSS). A baseline evaluation will occur at the time
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of randomization after the patient meets the inclusion criteria. Statistically significant
differences in baseline characteristics found between study groups will be controlled for
using the multiple logistic analysis approach. Please refer to Table 2 for description and
analysis of the baseline characteristics.

3.5 Methodology
3.5.1 Group Randomization & Blinding
Participants who enter the stroke centers who meet the inclusion and exclusion
criteria will be randomized in a 1:1 ratio to either the interventional (vitamin E alphatocopherol plus standard treatment) or control (standard treatment alone) group. This
randomization will be performed using a computerized program. Trained users will use the
computerized program to complete an eligibility checklist. If the program finds that the
patient is eligible then the patient will be enrolled and assigned to a randomization number.
Participants, research assistants, and physician investigator at every study site will be
blinded to the group assignment. All participants in both groups will be given the same
instructions on the use, benefits, and risks of the medications. Research assistants and
physician investigators will also be blinded to the primary, secondary, and safety outcome.
The clinical coordinator center located at the hub of the trial will be responsible for creating
and distributing study packets with either the placebo or the vitamin E tablet. The pharmacy
at each study site will assist in this process by ensuring that the placebo pills are identical
to the vitamin E alpha-tocopherol pills in appearance and taste. This method will allow for
standardization of delivery as well as ensuring that the participants, research assistants and
physician investigator are blinded to the intervention the participant receives at each study
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center. If any complications arise and the participant or provider needs to be un-blinded,
the clinical research coordinator may be contacted to identify what the participant received.

3.5.2 Intervention Design
Participants in the interventional group will receive clopidogrel and aspirin plus
vitamin E alpha-tocopherol. The initial loading dose on day 1 will include 3 oral tablets:
300mg clopidogrel, open label 72mg-300mg aspirin, and 200IU alpha-tocopherol. The
aspirin loading dose will be determined by the primary physician. All three medications
must be given within 12 hours of the primary event. The participants will receive a 20-day
supply of 75mg clopidogrel, 20-day supply of 200IU alpha-tocopherol, and 20-day supply
of 75mg aspirin. Patient’s will take one oral tablet of clopidogrel, alpha-tocopherol, and
aspirin by mouth once daily in the evening after eating a meal from day 2 to day 21. From
day 21 to day 90 study participants will discontinue the aspirin and continue protocol for
alpha-tocopherol and clopidogrel. Patient’s will receive a refill for clopidogrel and alphatocopherol at the follow-up appointments to encourage adherence.

3.5.3 Control Design
Participants in the control group will receive the standard treatment of clopidogrel
and aspirin plus placebo. The initial loading dose on day 1 will include 3 oral tablets:
300mg clopidogrel, open label 72mg-300mg aspirin, and a placebo tablet identical to that
of alpha-tocopherol. The aspirin loading dose will be determined by the primary physician.
All three medications must be given within 12 hours of the primary event. The participants
will receive a 20-day supply of 75mg clopidogrel, 20-day supply of placebo, and 20-day
supply of 75mg aspirin. Patient’s will take one oral tablet of clopidogrel, placebo, and
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aspirin by mouth once daily in the evening after eating a meal from day 2 to day 21. From
day 21 to day 90 study participants will discontinue the aspirin and continue the same
protocol for the placebo and clopidogrel. Patient’s will receive a refill for clopidogrel and
placebo at the follow-up appointments to encourage adherence.

3.5.4 Other Considerations
If the patient has yet to take the loading dose of 300mg clopidogrel and open label
72mg-300mg aspirin, then they will take it in conjunction with the alpha-tocopherol or
placebo supplement. If the patient has already received the clopidogrel, aspirin, or both, at
the time of randomization then they will take the alpha-tocopherol or placebo tablet
alongside the missing medication or alone. Patients should receive the oral vitamin E
supplements within 12 hours of the primary event. Participants who are admitted to the
hospital will be provided the daily oral vitamin E alpha-tocopherol supplements alongside
the clopidogrel or aspirin by their providing physician. When participants are discharged,
they will be instructed on the use of vitamin E alpha-tocopherol supplements. Instructions
will remain consistent among both the interventional and control groups.

3.6 Data Collection
The baseline characteristics described in Table 2 will be recorded at the time of
randomization by blinded researchers using the form found in Appendix B. Time will be
allocated to training research assistants on how to survey, utilize stroke scales, document
patient data, interpret laboratory values, and interpret radiologist neuroimaging results.
Stroke recurrence (hemorrhagic or ischemic) is the primary outcome and will be
measured utilizing a stroke free questionnaire (Appendix F) imaging. The patient will

50

undergo either a head computerized tomography (CT) scan or a magnetic resonance image
(MRI) scan that will be read by a neuroradiologist who will determine if there are signs of
an ischemic or hemorrhagic stroke. Imaging will be performed when symptoms arise
within 90 days of randomization or at the end of the trial at day 90. Patients will have
imaging done at the time of randomization to determine patient’s current stroke status and
a baseline image to compare future CT/MRI results.
The secondary outcome of change in disability will be measured at time of
randomization and at the end of the 90 days. Disability will be measured using the six
leveled modified Rankin Scale (mRS).3 Research assistants will be trained and given
Appendix D to determine the disability of each participant in both arms. Once the study is
complete, the mean change of disability within each group will be determined. The mean
change of disability between groups will then be analyzed.
In order to determine serum vitamin E alpha-tocopherol levels, we will collect
whole blood via peripheral blood draws at the end of the 3 months of each participant. For
accurate results, all participants must be fasting for 12-hours prior to the blood draw. Serum
alpha-tocopherol levels will be determined by using high-performance liquid
chromatography. The blood specimen will be collected in a red top tube and will be placed
in an amber vial to protect from light. If the specimen is unable to be analyzed within 7days then the specimen must be refrigerated or frozen and analyzed within 44 days. If the
blood specimen is grossly hemolyzed or has gross lipemia then it will be rejected. The
mean day 90 serum alpha-tocopherol levels will be compared between groups.
Myocardial infarction (MI), including fatal and non-fatal events, will be determined
by the providing physician who will use the Universal Definition of Myocardial Infarction
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algorithm that takes into account cardiac biomarkers, EKG abnormalities, imaging,
pathology, and clinical setting.2 When a patient presents with signs or symptoms of a MI
or there is a clinical suspicion by the provider, patients will undergo the standard testing.
Blinded research assistants will follow up with study participants at day 7 from
randomization to document verbal compliance and address any issues or concerns with
medication use or effects. The study participants will then have an appointment with a
blinded clinician at day 21 to ensure withdrawal of aspirin, continuation of vitamin E alphatocopherol and clopidogrel. At day 90 the study participants will have an in-person
appointment where trained blinded research assistants will measure the modified Rankin
Scale (mRS) score and the National Institute of Health Stroke Scale score as described in
Appendix D and E, respectively. At each visit, the participants will be questioned on stroke
recurrence since randomization and will be assessed for any stroke symptoms or signs
using the Questionnaire for Verifying Stroke-Free Status (QVSFS) detailed in Appendix
F.4 We will also ask about myocardial infarction events within the past 90 days. We will
also use patient medical and death records to support the measurement of our outcomes,
including all-cause mortality.

3.7 Adherence
Participants will be closely monitored throughout the trial. At day 7, 21 and 60, the
participants will have a follow up appointment with the clinicians. At the time of followup, they will receive a refill of the clopidogrel, aspirin, and alpha-tocopherol (or placebo)
supplements. At the appointment, participants will be asked if they have been adherent to
the medication using the Morisky scale. Patients will be considered adherent if they report
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at least moderate compliance. The inability to adhere to the medication will disqualify the
patient from participating in the trial.
Table 3: Proposed Trial Design Influenced by CHANCE and POINT trial 5,6
Measurements

Baseline/Screening/
Randomization Day 1

Eligibility

X

Signed Consent
Form
Randomization

X

Baseline
Characteristics/
Medical History
ABCD2 Score (for
TIA)
Modified Rankin
Scale (mRS)

X

NIHSS Score

X

Vital Signs

X

Basic Labs (CBC,
CMP)
Serum AlphaTocopherol Level
Head CT/MRI

X

EKG

X

Current
Medications
Stroke Free
Questionnaire
Medication
Adherence
Questionnaire
Medication Refill

X

Phone f/u
Day 7

Phone f/u
Day 21

Phone f/u
Day 60

In-person f/u
Day 90

Event Visit

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

3.8 Monitoring for Adverse Events
An adverse event is defined as an unexpected medical occurrence that happens
during pharmaceutical treatment. We will submit a data and safety monitoring plan that
will go into detail about collecting adverse events that will be performed by the clinical
research coordinator (CRC). A data monitoring center will be utilized to monitor all such
events throughout the trial. Participants will be closely monitored for any adverse events
throughout the entirety of the trial. All events will be documented, reported and included
in a final clinical study report. As a safety outcome, severe or moderate bleeding will be
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monitored for. If an adverse event occurs, the CRC may be contacted to unblind the
participant, research investigator, and primary physician to the intervention. Serious
adverse events will be reported to the IRB immediately. If bleeding occurs, then patients
will be instructed to stop the alpha-tocopherol tablets. In cases of serious active bleeding
and prolonged prothrombin time, vitamin K supplementation may be considered by the
primary physician.7
Table 4: GUSTO Criteria8
Severe Bleeding
Moderate Bleeding
Mild Bleeding

Intracranial hemorrhage or bleeding causing hemodynamic compromise requiring blood or fluids, inotropic
support to maintain blood pressure, surgical intervention (other than bleeding site repair), ventricular assist
devices or CPR to maintain cardiac output.
Bleeding requiring blood transfusions but does not cause hemodynamic compromise.
Bleeding that does not require transfusions nor cause hemodynamic compromise.

3.9 Sample Size Calculation
Our study aims to determine the difference in stroke recurrence among patients who
have a moderate to high-risk transient ischemic attack or minor ischemic stroke who
receive 200IU vitamin E alpha-tocopherol in addition to the standard treatment versus
those who receive the standard treatment alone. Taking into consideration the literature
discussed in the sample size literature review and using the Power and Precision software
(Appendix G), we determined that this trial will require at least 2,002 participants, with
1,001 participants per arm, in order to provide 80% power to detect a rate difference of
3.2% in the vitamin E alpha-tocopherol group, with a two-sided type I error of 0.05 and an
6% withdrawal rate, assuming an 8.2% event rate in the group of aspirin and clopidogrel
alone.
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3.10 Analysis
The statistical data will be analyzed using the intention-to-treat protocol by blinded
researchers. The statistical significance will be defined by a p-value less than 0.05. Our
dichotomous, primary outcome of stroke recurrence within 90 days will be measured as a
proportion in the control and intervention group. Therefore, the primary outcome will be
compared between groups using a chi-squared test. Because baseline characteristics and
other confounding variables may be associated with the dependent variable, multiple
logistic regression will be performed after the initial data analysis. To determine baseline
characteristic variation between the study arms, we will compare each variable using the
appropriate statistical analysis as suggested in Table 2.
Secondary outcomes include mean change in disability, mean serum vitamin E
alpha-tocopherol, proportion of myocardial infarction (MI), and proportion of all-cause
mortality. Mean change in disability, as measured by the mRS scale, from baseline to day
90 will be compared between groups using student’s t-test. Mean serum vitamin E alphatocopherol at day 90 will be compared between groups using student’s t-test. Proportion of
MI and all-cause mortality will both be compared between groups using chi-square
analysis.
We will analyze our data as a time to stroke recurrence using the Kaplan-Meier
survival analysis as a secondary analysis to investigate risk of stroke recurrence at different
time points. We will then use Cox proportional hazards regression to account for
confounding variables. We are confident in utilizing this analysis as a secondary approach
after calculating that only a few hundred participants are needed for this survival analysis.
This participant count is less than our proposed 2,002 participants.
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3.11 Timeline
The estimated total duration of the recruitment and data collection will be 32
months. The pre-enrollment phase will take approximately 6 months and will include
attaining central IRB approval, preparing and distributing the vitamin E alpha-tocopherol
to all study sites, and training research assistants at each study site how to survey, utilize
stroke scales, document patient data, interpret laboratory values, and interpret
neuroimaging results. We will allocate 20 months towards continuous enrollment and
follow-up. After halting recruitment, an additional 3 months will be given towards followup completion. Final data analysis will take approximately 6 months.
Table 5. Proposed Trial Timeline
Pre-enrollment Phase
(IRB approval,
Training)

Recruitment and Followup

Completion of FollowUp

Data Analysis &
Publication

6 MONTHS

20 MONTHS

3 MONTHS

6 MONTHS

Total Duration: 32 months
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CHAPTER 4: CONCLUSION
4.1 Strengths
We anticipate this trial to possess many strengths. First, the trial is novel in
investigating alpha-tocopherol’s proposed mechanism, in addition to dual antiplatelet
therapy (DAPT) of clopidogrel and aspirin, and the regimen’s potential efficacy in reducing
the proportion of stroke recurrence in patients with a transient ischemic attack (TIA) or
minor ischemic stroke compared to DAPT alone. The prospective study design allows for
the collection of specific data in real time unlike retrospective trials that are more prone to
biases and confounders. To increase the internal validity of the trial, we will implement a
strict randomization process, blind the participants and researchers, and have a placebo
group. Randomizing patients to either the control or interventional group utilizing a
computer-based program will aid in reducing selection bias and producing comparable
groups with respect to baseline characteristics. In addition, this trial will be double-blinded,
with the use of a randomized identification number and identical placebo supplement, to
reduce observer and confirmation bias. By increasing the validity of this trial, we will be
able to establish a relationship between vitamin E alpha-tocopherol and stroke recurrence.
We will also increase the external validity by having a multi-center trial design. Utilizing
the NIH Stroke Net, we will randomly select multiple stroke centers throughout the United
States to increase the generalizability of the trial.

4.2 Limitations
We anticipate our randomized, multi-center, double-blinded trial to have many
strengths, but also have a few limitations. First, we will be including only stroke centers
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within tertiary medical centers. While these hospitals treat the majority of stroke patients,
the study may not be generalizable to patients in more rural settings who lack the access to
tertiary medical centers and are treated primarily at rural hospitals. However, because the
majority of patients are treated at stroke centers that have the appropriate training and
resources, we feel that the inclusion of only these certified centers is the appropriate step
in determining a new treatment regimen to reduce the risk of stroke recurrence in patients
who experience a minor neurovascular event.
Another potential issue is the trial’s inability to enroll around the clock leading to
a possible convenient sample causing a potential selection bias and limiting the
generalizability of the study. Selection bias may also occur through the loss to follow up.
The trial is also at risk of information bias; however, we will attempt to reduce this with
the use of standard questionnaires, measurements and imaging results. We also will have
an extensive exclusion criterion that will exclude patients with a cardioembolic or
hemorrhagic stroke, mild TIA, moderate or severe ischemic stroke, hepatic insufficiency,
renal disease, and cardiac failure. Therefore, the sample size may not fully encompass all
stroke patients who are risk for a recurrent stroke. In addition, patients may have varying
vitamin E diet’s that may contribute to stroke recurrence and alter the levels of their serum
alpha-tocopherol levels. However, to accurately measure serum alpha-tocopherol levels,
the participant must be fasting for 12 hours prior to the blood draw. However, after our
primary analysis, we will perform secondary analysis of both multiple logistic regression
and cox-proportional hazards regression to control for confounding variables.
Given the trial’s novelty in delivering vitamin E alpha-tocopherol supplements in
addition to DAPT to stroke patients, we will administer a low dose of 200IU of alpha-
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tocopherol to reduce the risk of adverse effects, such as major bleeding, that may be seen
with higher dosing of 400IU, despite its positive results in the literature. If the addition of
200IU alpha-tocopherol does not result in an increased risk of moderate or major bleeding
then future directions could include an adaptive study design that could examine the effects
of different doses of vitamin E alpha-tocopherol with the use of a larger sample size.

4.3 Clinical Significance
Reducing the incidence of recurrent strokes would lessen the burden that exists for
healthcare professionals, including physician assistants, and reduce resource usage in
emergency departments and neurology units. According to the American Heart Association
statistics, stroke has a large healthcare burden with 800,000 strokes yearly, costing
approximately $34 billion a year.1 About 25% of these yearly strokes are recurrent,
suggesting an estimated cost of over $8.5 billion.1 Not only does stroke recurrence take a
toll on the healthcare system, but, more importantly, on the individual. According to a
study, a patient’s healthcare bill totals to $34,639 following discharge of a recurrent, noncardioembolic ischemic stroke. This is significantly higher than the $25,036 that is spent
for a new stroke occurrence.2 If we reduce the incidence of recurrent ischemic strokes in
this vulnerable population then their quality of life can be improved with a decrease in
mortality, morbidity and healthcare expenses.
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APPENDICES
Appendix A: Consent Form
Adapted from Consent for Participation in a Research Project, 200 FR.1 (2016-2)
YALE UNIVERSITY SCHOOL OF MEDICINE
Study Title: VITAMIN E ALPHA-TOCOPHEROLS TO PREVENT RECURRENT
STROKE IN PATIENTS WITH A MINOR NEUROVASCULAR EVENT
Principal Investigator: Charles Wira, MD
Invitation to Participate and Description of Project
You are invited to participate in a research study that is designed to look at the treatment
options for patients who have a transient ischemic attack (TIA) or minor ischemic stroke.
This study will specifically look at the addition of vitamin E supplements to the current
treatment regimen. You have been asked to participate in this study because you have
recently been diagnosed with a moderate to high-risk TIA or a minor stroke and are at high
risk for stroke recurrence.
In order to decide whether or not you wish to be a part of this research study, you should
know enough about the study’s risks and benefits to make an informed decision. This
consent form gives you detailed information about the research study, which a member of
the research team will discuss with you. This discussion should go over all aspects of this
research: the purpose, the procedures that will be performed, any risks of the procedures,
possible benefits and possible alternative treatments. Once you understand the study, you
will be asked if you wish to participate; if so, you will be asked to sign this form.
Description of Procedures
If you agree to participate in this study, you will be asked various questions regarding your
baseline characteristics including your age, gender, race, and past medical history. If you
have not had one already as part of your workup, you will undergo a computed tomography
(CT) scan or magnetic resonance imaging (MRI) prior to initiation to determine any
ischemic damage or presence of bleeding. A research assistant will then utilize a computer
system that will assign you to receive either vitamin E alpha-tocopherol supplements or
placebo pills (a pill causing no therapeutic benefit or harm) for a total of 90 days. In
addition, you will be assigned a unique identification number. Randomization through this
computer-based program ensures an equal chance for all participants to be assigned to
either group. The supplements will be taken as an adjunct to your dual antiplatelet treatment
of clopidogrel and aspirin.
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Once you are determined to have a minor ischemic stroke or a transient ischemic attack,
you will receive a loading dose of 300mg clopidogrel, 72mg-300mg aspirin (as determined
by the provider), and either 200IU vitamin E alpha-tocopherol or a placebo pill. You will
then be prescribed a 20-day course of 75mg clopidogrel and 75mg aspirin taken once daily
from day 2 to day 21. From day 22 to day 90, you will continue to take clopidogrel once
daily. From day 2 to day 90, you will be prescribed either 200IU vitamin E alphatocopherol or placebo supplements to be taken once daily. All medications should be taken
in the evening, together, with a meal. The treatments will be given as a monthly supply and
will be administered at the time of randomization. Your medication will be refilled at your
follow-up appointments.
-

-

-

DAY 1 you will receive:
o 300mg clopidogrel
o 72mg-300mg aspirin (dose determined by provider)
o 200IU vitamin E alpha-tocopherol OR placebo
DAY 2 to DAY 21
o 75mg clopidogrel
o 75mg aspirin
o 200IU vitamin E alpha-tocopherol OR placebo
DAY 22 to DAY 90
o 75mg clopidogrel
o 200IU vitamin E alpha-tocopherol OR placebo

You will be contacted via telephone for follow-up on days 7, 21, and 60 from time of
randomization. The follow-up appointments will include a questionnaire to assess for signs
and symptoms of a stroke and receive your medication refill. The study will conclude on
day 90 after your in-person appointment. At this appointment, you will undergo an MRI
and a questionnaire to assess for stroke recurrence. After the study is complete, we
recommend follow-up with your neurologist to determine next steps in your treatment plan.
A description of this study will be available on http://www.ClinicalTrials.gov, as required
by U.S. Law. This Web site will not include information that can identify you. At most,
the Web site will include a summary of this results. You can search this Web site at any
time.
You will be told of any significant findings that are developed during the course of your
participation in this study that may affect your willingness to continue to participate.
Research results will not be returned to your doctor. If research results are published, your
name and other personal information will not be given.
Risks & Inconveniences
Participation in this trial may place you at an increased risk of bleeding. Antiplatelet drugs,
including clopidogrel, aspirin, and vitamin E, are blood thinners that prevent blood cells
from clumping together to form a clot. Therefore, the addition of vitamin E to the standard
regimen may increase your risk of bleeding. Patient’s more commonly experience minor
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bleeding such as bruising easily or prolonged bleeding from minor cuts. However, though
rare, bleeding may occur in the brain, gastrointestinal tract, nosebleeds, eyes, etc. Bleeding
may require hospitalization, blood transfusions and cause fatality. If signs and/or symptoms
arise, you should go to the nearest hospital to be assessed and undergo diagnostic measures.
If bleeding occurs, this will be considered an adverse event and you may be withdrawn
from the study.
You may also experience other side effects related to the three medications. These side
effects include weakness, dizziness, nausea, abdominal pain, diarrhea, constipation and
other possible side effects listed on the label of each medication.
You will also receive exposure to radiation through computed tomography (CT) and/or
magnetic resonance imaging (MRI) as standard diagnostic measures for a stroke or
transient ischemic attack. A CT scan or MRI is required prior to randomization. Imaging
will aid in your diagnosis and in ruling out other possible causes of your symptoms and/or
signs such as brain bleeding, tumors, etc. At the end of the study, you will undergo an MRI
to aid in the diagnosis of a recurrent stroke.
Benefits
The results of this study may help the medical community in determining the most effective
treatment regimen for secondary prevention of recurrent strokes. A potential benefit of
taking vitamin E alpha-tocopherol supplements in addition to the clopidogrel and aspirin
is reducing the risk of recurrent strokes within 90 days of having a minor ischemic stroke
or transient ischemic attack. Reducing the risk of recurrent stroke may increase quality of
life and reduce disability severity.
Economic Considerations
Participation in this study is voluntary. No direct compensation will be given for
participation in this trial. You will be reimbursed for the vitamin E supplements, placebo
supplements, serum alpha-tocopherol blood draws, and other non-standard of care
procedures. If you are injured or become ill while on the study, seek immediate treatment
and contact the study doctor. If your illness is due to the study drug, vitamin E, you will
not be financially responsible. You will receive a parking voucher for your day 90 inperson appointment at the end of the trial.
Treatment Alternatives
The alternative is to deny participation in this study. If you decline participation into this
study then your primary medical provider will provide you your treatment plan for the
transient ischemic attack or minor ischemic stroke.
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Confidentiality
Information about your study participation will be entered into your Electronic Medical
Record (EMR). Once placed in your EMR, these results are accessible to all of your
providers who are appropriate to have access to your EMR (e.g., health insurance company,
disability provider.) The protected information that will be collected in this study includes
demographics, medical history, physical examinations, routine lab tests, current
medications, vital signs, CT/MRI results, and information recorded in study questionnaires.
Information about you and your health which might identify you may be used or given to:
•
•

•
•
•
•

•
•
•
•

The U.S. Department of Health and Human Services (DHHS) agencies
Representatives from Yale University and the Human Investigation Committee
(the committee or Institutional Review Board that reviews, approves, and
monitors research on human subjects), who are responsible for ensuring research
compliance. These individuals are required to keep all information confidential
Your providers who are participants in the Electronic Medical Record (EMR)
system
Those individuals at Yale who are responsible for the financial oversight of
research including billings and payments
The study doctor, Dr. Charles Wira, and the Yale study team
The U.S. Food and Drug Administration (FDA). This is done so that the FDA can
review information about the new drug product involved in this research. The
information may also be used to meet the reporting requirements of drug
regulatory agencies.
The study sponsor or manufacturer of study drug and/ or their representatives
Health care providers who provide services to you in connection with this study.
Laboratories and other individuals and organizations that analyze your health
information in connection with this study, according to the study plan.
Data and Safety Monitoring Boards and others authorized to monitor the conduct
of the Study

Any identifiable information that is obtained in connection with the study will remain
confidential and will be disclosed only with your permission or as required by the U.S. or
State law. Examples of information that we are legally required to disclose include abuse
of a child or elderly person, or certain reportable diseases. Study data will be kept
confidential through the use of encrypted servers and locked cabinets. When the results are
of the research are published or discussed in conferences, no information will be included
that would reveal your identity unless your specific consent for this activity is obtained.
All healthcare providers subject to HIPAA (Health Insurance Portability and
Accountability Act) are required to protect the privacy of your information. The research
staff at the Yale School of Medicine are required to comply with HIPAA and to ensure the
confidentiality of your information. Some of the individuals or agencies listed above may
not be subject to HIPAA and therefore may not be required to provide the same type of
confidentiality protection. They could use or disclose your information in ways not
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mentioned in this form. However, to better protect your health information, agreements are
in place with these individuals and/or companies that require that they keep your
information confidential.
By signing this form, you authorize the use and/or disclosure of the information described
above for this research study. The purpose of the uses and disclosures you are authorizing
is to ensure that the information relating to this research is available to all parties who may
need it for research purposes.
Voluntary Participation & Withdrawal
Participating in this study is voluntary. You are free to choose deny participation in this
study. Refusing to participate will involve no penalty or loss of benefits to which you are
otherwise entitled (such as your health care outside this study, the payment for your health
care, and your health care benefits). However, you will not be able to enroll in this research
study and will not receive study procedures as a study participant if you do not allow use
of your information as part of this study.
If you do become a subject, you are free to stop and withdraw from this study at any time
during its course. To withdraw from this study, you can call a member of the research team
at any time and tell them you no longer want to take part. This will cancel any future
appointments. The researchers may withdraw you from participating in the research if
necessary. You may be withdrawn if necessary. You may be withdrawn if you have a
serious side-effect related to vitamin E alpha-tocopherol such as moderate or major
bleeding events. You may also be withdrawn from the study if you do not adhere to the
treatment.
Withdrawing from the study at any time will involve no penalty or loss of benefits to which
you are entitled. Withdrawing will also not harm your relationship with your providers or
interfere with receiving standard treatment from your providers, if requested. When you
are withdrawn from the study, no new health information identifying you will be gathered
after that date. Information that has already been gathered may still be used and given to
others until the end of the research study, as necessary to ensure the integrity of the study
and/or study oversight.
Questions
We have used some technical terms in this form. Please feel free to ask about anything you
don’t understand and to consider this research and the permission from carefully – as long
as you feel it necessary – before you make a decision.
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Authorization
I have read (or someone has read to me) this form and have decided to participate in the
project described above. In general purposes, the particulars of my involvement and
possible hazards and inconveniences have been explained to my satisfaction. My signature
also indicates that I have received a copy of this consent form.
________________________________
Name of Subject
________________________________
Signature

_____________
Date

________________________________
Signature of Person Obtaining Consent

_____________
Date

If you have any further questions about this project or if you have a research related
problem, you may contact the co-investigator Veronica Guirguis at
veronica.guirguis@yale.edu.
If, after you have signed this form you have any questions about your privacy rights,
please contact the Yale Privacy Officer at (203) 432-5919. If you would like to talk with
someone other than the researchers to discuss problems, concerns and questions you may
have concerning this research, or to discuss your rights as a research subject, you may
contact the Yale Human Investigation Committee at (203) 785-4688.
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Appendix B: Baseline Characteristics Survey

Participant Number: __________________

Research Assistant: ___________________

Research Center: _____________________

Date: ____________

Study Setting: ______________________
Demographics:
Age: ___________
Gender: ___________
Race: ___________
Please Check Below if Participant Has the Following:
Hypertension _____
Ischemic Heart Disease _____
Diabetes Mellitus _____
Smoking History
If yes: Current? Former?
How many cigarettes a day?
How many years?
Clopidogrel Use
If yes: What is the dose?
For how long?
Aspirin Use
If yes: What is the dose?
For how long?
ABCD2 Score (if TIA): ___________
NIHSS Score (if ischemic stroke): ___________
Modified Rankin Scale (mRS) Score: ___________
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Baseline Laboratory Values:
Laboratory Test
PT
PTT
INR
Alpha-tocopherol
Total Cholesterol (mg/dL)
LDL (mg/dL)
HDL (mg/dL)
Triglycerides (mg/dL)
Chol/HDL Ratio (calculated)
Non-HDL Cholesterol (mg/dL, calculated)
WBC (K/uL)
RBC (M/uL)
Hgb (gm/dL)
Hct (%vol)
MCV (fl)
Platelets (k/uL)
MCH (pg)
MCHC (g/dL)
RDW (%)
MPV (fl)
Neutrophils (%)
Lymphocytes (%)
Eosinophils (%)
Basophils (%)
Neutrophils (K/uL)
Lymphocytes (K/uL)
Monocytes (K/uL)
Basophils (K/uL)
Eosinophils (K/uL)
Serum Creatinine (mg/dL)
BUN (mg/dL)
Estimated GFR (mg/dL)
BUN/Cr Ratio
Glucose (mg/dL)
Sodium (mmol/L)
Potassium (mmol/L)
Chloride (mmol/L)
Carbon Dioxide (mmol/L)
Calcium (mg/dL)
Alkaline Phosphatase (U/L)
Aspartate Aminotransferase (U/L)
Alanine Aminotransferase (U/L)
Bilirubin, Total (mg/dL)
Protein, Total (g/dL)
Albumin (g/dL)
Globulin (g/dL)
A/G Ratio
Anion Gap

Laboratory Value
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Appendix C: ABCD2 Score1
FOR TIA PATIENTS (SCORE MUST BE ≥ 4 TO QUALIFY)
ABCD2 Score: ____/7
Age ≥ 60 years

No
(0 points)

Yes
(1 point)

BP ≥140/90 (initial BP. Either
SBP ≥ 140 or DBP ≥ 90)

No
(0 points)

Yes
(1 point)

Clinical Features of the TIA

Other
Symptoms
(0 points)

Speech
Disturbance
without
Weakness (1
point)

Unilateral
Weakness (2
points)

Duration of Symptoms

<10 minutes
(0 points)

10-59 minutes (1
point)

≥60 minutes (2
points)

History of Diabetes

No (0 points)

Yes (1 point)
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Appendix D: Modified Rankin Scale (mRS)2
FOR ALL PATIENTS
Modified Rankin Scale (mRS) Score:
Level

Description

0

No symptoms

1

No significant disability; able to perform usual activities

2

Slight disability: able to carry out own affairs but unable to perform previous activities without assistance

3

Moderate disability: require some assistance but is able to walk without help

4

Moderately-Severe disability; unable to walk or attend to bodily needs without assistance

5

Severe disability; bedridden, incontinent, requires nursing care

6

Death
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Appendix E: National Institute of Health Stroke Scale (NIHSS)3
Minor ischemic stroke patients at time of randomization (score must be ≤ 3 to qualify)
For all patients on day 90
NIHSS Score: ___/ 42
+0

+1 POINT

Consciousness

Alert, keenly
responsive

Arouses to minor
stimulation

Ask Month &
Age
‘Blink eyes’
‘Squeeze
hands’

Both questions right

1 question right OR
Dysarthric/intubated/traum
a/ language barrier

Perform both tasks

Performs 1 task

Normal

Partial gaze palsy: can be
overcome OR
Partial gaze palsy corrects
with oculocephalic reflex
Partial hemianopia

Horizontal
Extraocular
Movements
Visual Fields

No visual loss

Facial Palsy

Normal symmetry

Left Arm
Motor Drift
Right Arm
Motor Drift
Left Leg
Motor Drift
Right Leg
Motor Drift

Limb Ataxia

Sensation

Language/
Aphasia

Dysarthria

Extinction/
inattention

No drift for 10 sec OR
Amputation/joint
fusion
No drift for 10 sec OR
Amputation/joint
fusion
No drift for 5 sec OR
Amputation/joint
fusion
No drift for 5 sec OR
Amputation/joint
fusion
No ataxia OR
Amputation/joint
fusion OR
Doesn’t understand
OR
Paralyzed

Normal/no sensory
loss

Normal/no aphasia

Normal OR
Intubated/Unable to
rest

No abnormality

Minor paralysis (flat
nasolabial fold, smile
asymmetry)
Drift, but doesn’t hit bed
Drift, but doesn’t hit bed
Drift, but doesn’t hit bed
Drift, but doesn’t hit bed

Ataxia in 1 limb

Mild-moderate loss: less
sharp/duller OR
Mild-moderate loss: can
sense being touched
Mild-moderate aphasia:
some obvious changes,
without significant
limitation

Mild-moderate dysarthria:
slurring but can be
understood
Visual/tactile/auditory/spat
ial/personal inattention OR
Extinction to bilateral
simultaneous stimulation

+2 POINTS
Requires repeated
stimulation to arouse
OR
Movements to pain
0 questions right OR
Aphasic

+3 POINTS

+4
POINTS

Postures or
Unresponsive

Perform 0 tasks

Forced gaze palsy:
cannot be overcome
Complete
hemianopia

Partial paralysis
(lower face)
Drift, hits bed OR
Some effort against
gravity
Drift, hits bed OR
Some effort against
gravity
Drift, hits bed OR
Some effort against
gravity
Drift, hits bed OR
Some effort against
gravity

Bilaterally blind OR
Bilateral hemianopia
Unilateral complete
paralysis (upper/lower
face) OR
Bilateral complete
paralysis (upper/lower
face)
No effort against
gravity

No
movement

No effort against
gravity

No
movement

No effort against
gravity

No
movement

No effort against
gravity

No
movement

Ataxia in 2 limbs

Complete loss: can’t
sense being touched
at all OR
No response &
quadriplegic OR
Coma/unresponsive
Severe aphasia:
fragmentary
expression, inference
needed, can’t identify
materials
Severe dysarthria:
unintelligible slurring
or out of proportion
to dysphasia OR
Mute/anarthic
Profound hemiinattention (ex: does
not recognize own
hand) OR
Extinction to >1
modality

Mute/global aphasia:
no usable
speech/auditory
comprehension OR
Coma/unresponsive
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Appendix F: Patient Follow-Up
Participant Identifying Number: ___________
Stroke Center Site: ___________
Name of Researcher: ___________
Today’s Date: ___________
Known Recurrent Stroke? ___________
If yes, how many days after your index stroke? ___________
Known Myocardial Infarction?
If yes, how many days after your index stroke? ___________

Medication Compliance:
Morisky Scale Score: ___________

Disability
Modified Rankin Scale Score: ___________
NIHSS Score (only if index event was minor ischemic stroke): ___________

Labs and Imaging (for day 90 only)
Serum alpha-tocopherol level: ___________
Notable Labs (out of normal range):

MRI Findings (evidence of new infarction): ________________________________
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Questionnaire for Verifying Stroke-Free Status (QVSFS)4
1. Were you ever told by a physician that you had a stroke? (since last visit)
___ Yes

___ No

___ Unknown

2. Were you ever told by a physician that you had a TIA, ministroke, or transient
ischemic attack? (since last visit)
___ Yes
___ No
___ Unknown

3. Have you had sudden painless weakness on one side of your body?
___ Yes

___ No

___ Unknown

4. Have you had sudden numbness or a dead feeling on one side of your body? (since
last visit)
___ Yes
___ No
___ Unknown

5. Have you had sudden painless loss of vision in one or both eyes? (since last visit)
___ Yes

___ No

___ Unknown

6. Have you suddenly lost one half of your vision? (since last visit)
___ Yes

___ No

___ Unknown

7. Have you suddenly lost the ability to understand what people are saying? (since last
visit)
___ Yes
___ No
___ Unknown

8. Have you ever suddenly lost the ability to express yourself verbally or in writing?
(since last visit)
___ Yes
___ No
___ Unknown
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Appendix G: Sample Size Calculation

Using the Power and Precision 4, we determined that the trial will require at least 2,002
participants, with 1,001 participants per arm, in order to provide 80% power to detect a rate
difference of 3.2% in the vitamin E alpha-tocopherol group, with a two-sided type I error
of 0.05 and an 6% withdrawal rate, assuming an 8.2% event rate in the group of aspirin
and clopidogrel alone.
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